Introduction
============

Statins are widely used for the treatment of hypercholesterolemia and to decrease the risk of cardiovascular disease ([@b1-etm-0-0-3547]). Statins act by inhibiting the conversion of HMG-CoA to mevalonate, which is a rate-limiting step in the cholesterol biosynthesis pathway and thus lowering the LDL-cholesterol in the blood ([@b2-etm-0-0-3547]). Previous clinical trials have demonstrated that statins are able to substantially decrease cardiovascular-associated morbidity and mortality in patients with and without coronary disease ([@b3-etm-0-0-3547]--[@b5-etm-0-0-3547]). Since serum cholesterol levels have been closely associated with coronary artery disease ([@b6-etm-0-0-3547]), it was initially hypothesized that the ability of statins to lower cholesterol levels was the predominant mechanism underlying the observed reduction in the risk of cardiovascular diseases ([@b7-etm-0-0-3547]). However, it has since emerged that the therapeutic benefits of statins may not solely be explained by their cholesterol-lowering effects ([@b8-etm-0-0-3547],[@b9-etm-0-0-3547]); it was reported that patients treated with statins were less susceptible to cardiovascular incidents, independent of cholesterol lowering ([@b10-etm-0-0-3547]). Therefore, mechanisms other than cholesterol-lowering may underlie the ability of statins to protect against cardiovascular incidents.

Statins have been shown to directly improve endothelial function and promote vascular relaxation by increasing the synthesis of nitric oxide by endothelial nitric oxide synthase (eNOS) ([@b11-etm-0-0-3547]), and by reducing the levels of angiopoietin-2 ([@b12-etm-0-0-3547]), which are important regulatory factors in endothelial cells for protection against the development of arteriosclerosis ([@b13-etm-0-0-3547],[@b14-etm-0-0-3547]). In addition, statins promote atherosclerotic plaque stability ([@b15-etm-0-0-3547]) and decrease the production of reactive oxygen species from monocytes and macrophages ([@b16-etm-0-0-3547]). Furthermore, statins reduce pro-inflammatory cytokine expression and oxygen radical formation ([@b17-etm-0-0-3547]--[@b19-etm-0-0-3547]), while they are also associated with a reduced risk of Alzheimer\'s disease ([@b1-etm-0-0-3547]). Impairment of vascular endothelial cells, which may result from increased production of reactive oxygen species and decreased synthesis or secretion of endothelial-derived nitric oxide ([@b20-etm-0-0-3547]--[@b22-etm-0-0-3547]), has been shown to be involved in the pathogenesis of arteriosclerosis and other cardiovascular diseases ([@b23-etm-0-0-3547]). Therefore, maintenance of vascular endothelial function is important to prevent cardiovascular disease ([@b24-etm-0-0-3547],[@b25-etm-0-0-3547]). However, to the best of our knowledge, no previous study has systematically investigated the effects of statins on endothelial cells, and thus it is difficult to mechanistically illustrate their beneficial clinical effects.

Therefore, the present study used cDNA microarrays to investigate the effect of lovastatin on global gene expression patterns in human umbilical vein endothelial cells (HUVECs), in order to identify unknown intracellular targets of statins and potential mediators of the pleiotropic effects observed for this drug. The results of the present study may provide further insights into the mechanisms underlying the pleiotropic effects of statins and their anti-atherogenic potential.

Materials and methods
=====================

### Reagents

Lovastatin (Sigma-Aldrich, St. Louis, MO, USA)was converted to an active form as described previously ([@b26-etm-0-0-3547]). Briefly, inactive lovastatin was dissolved in warm (55°C) ethanol, followed by the addition of 0.6 M NaOH and H~2~O, and was incubated at room temperature for 30 min. Subsequently, HCl was used to adjust the final solution to pH 8.0, and the lovastatin solution was stored as a 10 mM stock at −20°C. Rabbit polyclonal anti-SGK3 (1:1,000, ab153981), rabbit monoclonal anti-ATP2B1 (1:1000, ab190355), rabbit monoclonal anti-PTK2B (1:1,000, ab32571), rabbit polyclonal anti-eNOS (1:1,000, ab5589), rabbit monoclonal anti-MAP3K3 (1:2,000, ab40756) and rabbit polyclonal MAP4K3 (1:2,000, ab103481) antibodies were purchased from Abcam (Cambridge, MA, USA). In addition, rabbit polyclonal anti-BCL2 (1:1,000, 2872), rabbit monoclonal anti-BAX (1:1,000, 5023), mouse monoclonal anti-caspase-3 (1:500, 9668), mouse monoclonal anti-AKT(1:2,000, 2920), rabbit monoclonal anti-p-AKT (1:1,000, 4060) and mouse monoclonal β-actin (1:5,000, 3700) antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).

### Cell culture

HUVECs were purchased from ATCC (Manassas, VA, USA) and maintained in Dulbecco\'s modified Eagle\'s medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.). Cells were cultured at 37°C in a 5% CO~2~ atmosphere until further use, and were seeded in 6-well plates at a density of 4×10^5^ cells per well. For dose-response experiments, the cells were treated with various concentrations of lovastatin for 24 h (0.1, 0.5, 2.5 and 12.5 µM). For time-course experiments, the cells were treated with 0.5 µM lovastatin for various durations (2, 6, 12 and 24 h). Control cells were treated with 0.1% dimethyl sulfoxide (vehicle).

### Cellular cholesterol measurement

Total cholesterol was extracted from the cells according to a previously described method ([@b27-etm-0-0-3547]), with minor modifications. Briefly, cells were harvested and washed twice with phosphate-buffered saline (PBS). Next, extraction was performed with 1 ml isopropanol, followed by sonication for 20 min at 4°C, and centrifugation at 10,000 × g for 10 min at 4°C. The supernatant was evaporated under a vacuum and the pellet was resuspended in 20 µl isopropanol for the determination of cellular cholesterol. Cholesterol levels were measured using a Total Cholesterol Detection kit (1021; Jiemen Biotechnology Corp., Shanghai, China). Subsequently, the sediment fractions were lysed using a Mammalian Cell Extraction kit (K269-500; BioVision, Inc., Milpitas, CA, USA), and total protein levels were quantified using the Bradford method (P0006; Beyotime Institute of Biotechnology).

### cDNA microarray

Total RNA was extracted from the cells using TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.), followed by purification on an RNeasy column (74104; Qiagen, Inc., Valencia, CA, USA) and quantification by UV absorption using a 2000 Nanodrop spectrophotometer (Thermo Fisher Scientific, Inc., Wilmington, DE, USA). RNA quality was assessed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Inc., Santa Clara, CA, USA). A cDNA microarray analysis was conducted according to a previous study ([@b28-etm-0-0-3547]). Briefly, a home-made microarray was used and reverse transcription was done using an Ambion RETROscript reverse transcription kit (AM1710). Samples from three wells of the vehicle-treated group were pooled and used as a reference to label Cy3 (GE Healthcare Life Sciences). RNA from the drug treated cells was isolated in triplicate and labeled with Cy5 individually. Cy3- and Cy5-labeled cDNA pools were mixed to hybridize. Hybridization was performed at 56°C for 16 h and washes were performed and followed by scanning on an Axon 4000B Scanner (Axon Instruments, Sunnyvale, CA, USA). In total 8,583 genes/expressed sequence tags were selected according to signal intensity. Gene expression profiling for each time point was conducted with Significance Analysis of Microarrays software, version 2.20 (<http://statweb.stanford.edu/~tibs/SAM/>), with One Class response type (false discovery rate \<0.01). Genes were considered as differentially expressed when their fold-change was \>1.5-fold. The function of these differentially-expressed genes was searched with bioinformatics tools including KEGG (<http://www.genome.jp/kegg/>) and DAVID (<https://david.ncifcrf.gov/>) pathway analysis.

### Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

A total of 2 µg of total RNA was used for reverse transcription using an Ambion RETROscript reverse transcription kit (AM1710). Next, the cDNA was diluted 1:20 for RT-qPCR. RT-qPCR was conducted on an ABI 7300 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) with SYBR Green I fluorescent dye (Toyobo Co., Ltd., Osaka, Japan). The PCR reaction contained 1 µl of cDNA, 1 µl of primers (5 µM), 8 µl of H~2~O and 10 µl of reaction mixture with a total volume of 20 µl. The reactions were performed in triplicate at 94°C for 15 s and 60°C for 1 min and 40 cycles. *GAPDH* was used as an internal control. Gene expression was evaluated with the 2^−∆∆Ct^ method ([@b27-etm-0-0-3547]). The primer sequences of the genes used for qPCR were designed with primer express 2.0 and are listed in [Table I](#tI-etm-0-0-3547){ref-type="table"}.

### Cell counting kit (CCK)-8 assay

Following the treatment of HUVECs with various concentrations of lovastatin for 24 h or 0.5 µM lovastatin for various durations, cell viability was determined by adding 10 µl CCK-8 solution (Dojindo Molecular Technologies, Inc., Kumamoto, Japan), followed by incubation at 37°C for 2 h. Absorbance at 450 nm was measured using a SpectraMax 190 Microplate Reader (Molecular Devices, LLC, Sunnyvale, CA, USA). In each assay, four parallel wells were run and experiments were conducted in triplicate. In addition, cells were treated with oxidized (ox)-low-density lipoprotein (LDL),lovastatin or both for 24 h, and then measured with CCK-8 as described above, to assess the protective effect of lovastatin on injury induced by ox-LDL.

### Cell apoptosis assay

To investigate the apoptosis of HUVECs, the cells were seeded at a density of 2×10^5^ cells/well in a 6-well plate and incubated at 37°C overnight. Subsequently, the cells were treated with ox-LDL, lovastatin or both for 24 h, detached with 0.25% trypsin digestion and washed with cooled PBS. Next, cells were collected and resuspended in binding buffer containing Annexin-V and propidium iodide (Beyotime Institute of Biotechnology) and incubated for 15 min in the dark at room temperature. Apoptosis analyses were performed on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).

### Western blot analysis

HUVECs were washed twice with ice-cold PBS and lysed in radioimmunoprecipitation assay buffer (50 mM Tris, 150 mM NaCl, 1% Triton X-100, 0.1% SDS and 1% sodium deoxycholate; Beyotime Institute of Biotechnology, Haimen, China) containing protease and phosphatase inhibitors. Next, equal volumes of protein (10 µg) were separated by 12% SDS-PAGE and transferred to Hybond-C nitrocellulose membranes (GE Healthcare Life Sciences, Little Chalfont, UK) in transfer buffer (192 mM glycine, 25 mM Tris, 2.5 mM SDS, 10% methanol). The blots were blocked with 5% nonfat milk in Tris-buffered saline supplemented with Tween-20 for 1 h at room temperature, followed by incubation with primary antibodies overnight at 4°C. Subsequently, the membranes were incubated with horseradish peroxidase-conjugated secondary antibody (anti-rabbit IgG, 1:2,000; 7074; anti-mouse IgG, 1:2,000, 7076; Cell Signaling Technology, Inc.). The blots were developed with ECL Plus Western Blotting Detection Reagent (GE Healthcare Life Sciences) and analyzed using ImageJ software (1.43b; National Institutes of Health, Bethesda, MD, USA).

### RNA silencing

Accell small interfering (si)RNA targeting *PTK2B* was purchased from GE Dharmacon (GE Healthcare Life Sciences), with a scrambled siRNA used as the control (GE Healthcare Life Sciences). Transfection of HUVECs with *PTK2B* siRNA or scrambled siRNA was performed using Lipofectamine RNAiMAX (Thermo Fisher Scientific, Inc.), according to the manufacturer\'s instructions.

### Statistical analysis

Data are presented as the mean ± standard deviation. Comparisons between groups were conducted by one-way analysis of variance and least significant difference using SPSS software, version 19.0 (IBM SPSS, Armonk, NY, USA). P\<0.05 were considered to indicate a statistically significant difference.

Results
=======

### Effects of lovastatin on the cholesterol content of HUVECs

The effect of lovastatin on intracellular cholesterol content was evaluated. Lovastatin (0.5, 2.5 and 12.5 µM) significantly decreased the cholesterol content of HUVECs following 24 h of incubation (P\<0.05; [Fig. 1A](#f1-etm-0-0-3547){ref-type="fig"}). Notably, the cholesterol content was not significantly different between the 0.5, 2.5 and 12.5 µM lovastatin-treated cells (P\>0.05; [Fig. 1A](#f1-etm-0-0-3547){ref-type="fig"}); therefore, 0.5 µM lovastatin was used for the time-course experiment. As shown in [Fig. 1B](#f1-etm-0-0-3547){ref-type="fig"}, lovastatin significantly decreased the cholesterol content of HUVECs following 12 and 24 h of treatment (P\<0.05), but not after 2 or 6 h of treatment (P\>0.05). Therefore, the duration of treatment with 0.5 µM lovastatin was set at 2 and 24 h, in order to observe short- and long-term gene expression profiles, which may be dependent or independent of cholesterol lowering.

### Effects of lovastatin on the gene expression profile of HUVECs

cDNA microarrays were used to analyze the effects of 0.5 µM lovastatin on the gene expression profile of HUVECs after 2 and 24 h of treatment. The results indicated that the expression levels of a number of genes were altered by lovastatin. After 2 h of treatment with 0.5 µM lovastatin, 12 genes were downregulated and 178 genes were upregulated, with fold-changes of \>1.5 (data not shown). Similarly, after 24 h of treatment with 0.5 µM lovastatin, 33 genes were downregulated and 77 genes were upregulated, presenting fold-changes of \>1.5 (data not shown). These genes may represent unknown intracellular targets of lovastatin and require further clarification.

Subsequently, the genes that were differentially expressed at 2 and 24 h of treatment were compared to identify which genes were altered at both treatment durations, since these may serve important roles in the effects of lovastatin on endothelial cells. As shown in [Fig. 1C](#f1-etm-0-0-3547){ref-type="fig"}, 4 genes were downregulated at both 2 and 24 h of treatment, including *OVGP1*, *SNPH*, *RAB25* and *TMCO1*, whereas the *ATP2B1*, *FLJ43663*, *C7orf29*, *SGK3*, *TM4SF4*, *SLK*, *BCL2*, *CNTNAP1* and *PTK2B* genes were upregulated at 2 and 24 h of treatment (the fold change is summarized in [Fig. 1D](#f1-etm-0-0-3547){ref-type="fig"}). According to the known functions of these genes, such as SGK3, ATP2B1 and PTK2B involved in cell proliferation and survival, ([@b29-etm-0-0-3547]--[@b31-etm-0-0-3547]), it may be hypothesized that they are independent of the cholesterol-lowering effects of lovastatin and likely respond to lovastatin as early as 2 h after treatment. Therefore, further investigation into the biological significance of these genes may be important.

### Critical genes regulated by lovastatin in HUVECs

The results of the cDNA microarray analysis were verified by qPCR. As is shown in [Fig. 2A](#f2-etm-0-0-3547){ref-type="fig"}, the qPCR results for the majority of genes were consistent with the microarray results, including the upregulation of *BCL2*, *PTK2B*, *MAP3K3*, *MAP4K2*, *ATP2B1* and *SGK3*, and the downregulation of *SNPH*, *RAB25* and *OVGP1*. Whether alterations in the expression levels of these genes resulted in alterations in protein expression was unclear. Therefore, the protein expression levels of certain important genes (according to their known function) were analyzed by western blot analysis. The results demonstrated that SGK3, ATP2B1, PTK2B, BCL2 and MAP3K3 were all upregulated by lovastatin, which was consistent with the alteration of their gene expression levels, with the exception of MAP4K2 ([Fig. 2B](#f2-etm-0-0-3547){ref-type="fig"}). Since SGK2, ATP2B1, PTK2B and MAP3K3 are associated with cell proliferation and survival ([@b29-etm-0-0-3547]--[@b32-etm-0-0-3547]), and BCL2 is an anti-apoptosis protein ([@b33-etm-0-0-3547]), it may be hypothesized that lovastatin may affect cell proliferation. However, the viability of HUVECs was not significantly altered by lovastatin following 24 h of treatment (P\>0.05; [Fig. 2C](#f2-etm-0-0-3547){ref-type="fig"}).

### Lovastatin protects HUVECs against ox-LDL-induced cytotoxicity via the PTK2B/AKT signaling pathway

Since lovastatin did not affect the viability of HUVECs after 24 h of treatment, the ability of lovastatin to protect HUVECs against ox-LDL-induced cytotoxicity was investigated. As is shown in [Fig. 3A](#f3-etm-0-0-3547){ref-type="fig"}, 20 µg/ml ox-LDL significantly reduced the viability of HUVECs after 24 h of treatment (P\<0.05). Although lovastatin did not significantly affect the viability of HUVECs after 24 h of treatment, it was able to significantly protect HUVECs against ox-LDL-induced injury (P\<0.05). In addition, the ability of lovastatin to protect HUVECs against ox-LDL-induced apoptosis was evaluated ([Fig. 3B and C](#f3-etm-0-0-3547){ref-type="fig"}). Annexin V-positive cells were significantly decreased in the lovastatin plus ox-LDL group, as compared with the ox-LDL group (P\<0.05; [Fig. 3C](#f3-etm-0-0-3547){ref-type="fig"}), thus further supporting the protective role of lovastatin against ox-LDL-induced HUVEC cytotoxicity.

In the western blot analysis, both PTK2B and BCL2 were upregulated in the lovastatin-treated HUVECs. Since PTK2B serves an important role in cell survival via the AKT pathway ([@b34-etm-0-0-3547]), and BCL2 is a major anti-apoptotic protein in mitochondrial-dependent apoptosis, it may be hypothesized that this pathway plays an important role in lovastatin-mediated protection against ox-LDL-induced cell injury. As is shown in [Fig. 3D](#f3-etm-0-0-3547){ref-type="fig"}, ox-LDL treatment was associated with a downregulation of PTK2B and its downstream p-AKT and eNOS, as well as downregulation of BCL2 and upregulation of the pro-apoptotic protein BAX and cleaved caspase-3. These results suggested that ox-LDL exerted pro-apoptotic effects on mitochondrial-dependent apoptosis. However, treatment with lovastatin was able to reverse these alterations in protein expression, including upregulating PTK2B, p-AKT, eNOS and BCL2, and downregulating BAX and cleaved caspase-3. These alterations in protein expression levels were in parallel with cell viability and apoptosis assays, thus suggesting that these proteins may serve critical roles in lovastatin-mediated protection against ox-LDL-induced cell injury.

### Knockdown of PTK2B attenuates ox-LDL-induced HUVEC injury

AKT is known to promote cell survival by upregulating the expression of BCL2 and downregulating the expression of BAX ([@b35-etm-0-0-3547]). In addition, PTK2B has been shown to be an upstream protein of AKT and eNOS ([@b36-etm-0-0-3547]). Therefore, it may be hypothesized that PTK2B promotes the AKT/BCL2 signaling cascade. To test this hypothesis, PTK2B expression in HUVECs was transiently knocked down for 48 h using siRNA, after which HUVECs were treated with ox-LDL for 24 h to observe the effect of PTK2B on cell viability and apoptosis. The results demonstrated that silencing of *PTK2B* expression significantly decreased cell viability, thus indicating its importance for cell survival in HUVECs ([Fig. 4A](#f4-etm-0-0-3547){ref-type="fig"}). Notably, knockdown of PTK2B was able to markedly reduce ox-LDL-induced cytotoxicity. Subsequently, the ox-LDL-induced apoptosis of HUVECs following knockdown of *PTK2B* was analyzed. The ability of ox-LDL to induce apoptosis of HUVECs was markedly compromised following knockdown of *PTK2B* ([Fig. 4B and C](#f4-etm-0-0-3547){ref-type="fig"}). Furthermore, we examined the signaling cascade involved in this pathway. As is shown in [Fig. 4D](#f4-etm-0-0-3547){ref-type="fig"}, PTK2B was downregulated following treatment of HUVECs with ox-LDL and siRNA, although the extent of ox-LDL-induced PTK2B downregulation was markedly reduced in *PTK2B* knockdown cells. Accordingly, the ox-LDL-induced inhibition of p-AKT and eNOS, downregulation of BCL2 and upregulation of BAX and cleaved caspase-3 were greatly compromised following knockdown of *PTK2B*. These results suggest that the PTK2B-mediated signaling pathway is upregulated by lovastatin and serves an important role in the lovastatin-mediated protection against ox-LDL-induced cytotoxicity.

Discussion
==========

In the present study, cDNA microarrays were used to identify unknown intracellular targets of lovastatin and potential mediators of the previously observed pleiotropic effects of lovastatin ([@b37-etm-0-0-3547]). In addition, the gene expression profiles for HUVECs treated with lovastatin at various concentrations and durations were presented.

The present study compared the genes regulated after 2 and 24 h of lovastatin treatment. The results demonstrated that 13 genes were consistently altered following lovastatin treatment for the two different durations, including 4 genes that were downregulated (*OVGP1*, *SNPH*, *RAB25* and *TMCO1*) and 9 genes that were upregulated, such as *ATP2B1*, *FLJ43663*, *C7orf29*, *SGK3*, *TM4SF4*, *SLK*, *BCL2*, *CNTNAP1* and *PTK2B*. Subsequently, the functions of these genes were searched in the Uniprot and PubMed databases in order to obtain useful information for further study; however, only a few of the genes were associated with cell proliferation or survival, including *SGK3*, *BCL2* and *PTK2B*, which were upregulated. *SGK3* is serine/threonine-protein kinase that is involved in the regulation of numerous ion channels, cell proliferation, survival and migration ([@b38-etm-0-0-3547],[@b39-etm-0-0-3547]). BCL2 is a well-known anti-apoptotic protein in the mitochondrial-dependent apoptosis signaling pathway. *PTK2B* encodes a cytoplasmic protein tyrosine kinase that is involved in calcium-induced regulation of ion channels and activation of phosphatidylinositol 3-kinase and the AKT signaling cascade ([@b40-etm-0-0-3547],[@b41-etm-0-0-3547]), as well as activation of the MAPK signaling cascade ([@b42-etm-0-0-3547],[@b43-etm-0-0-3547]). Therefore, the authors of the present study hypothesized that lovastatin may promote cell viability via the upregulation of *SGK3*, *PTK2B* and *BCL2*. However, cell apoptosis and viability assays demonstrated that lovastatin did not affect HUVEC viability. These results suggested that lovastatin may exert its beneficial effects via a different mechanism. Therefore, the protective effect of lovastatin against ox-LDL-induced HUVEC cytotoxicity was then investigated.

ox-LDL serves a major role during atherogenesis ([@b44-etm-0-0-3547]), impairs endothelial vasodilator function ([@b45-etm-0-0-3547],[@b46-etm-0-0-3547]) and stimulates apoptosis ([@b47-etm-0-0-3547],[@b48-etm-0-0-3547]). In the present study, lovastatin was able to protect HUVECs against ox-LDL-induced cytotoxicity and cell apoptosis, thus suggesting that some unidentified mechanisms may exist underlying this effect. PTK2B is known to activate the AKT survival pathway to promote BCL2 upregulation, while AKT is an upstream regulator of eNOS, which serves an important role in the protection against ox-LDL ([@b49-etm-0-0-3547],[@b50-etm-0-0-3547]). Based on these previous observations, and since lovastatin upregulated the expression of *PTK2B* and *BCL2* in the current study, the AKT/BCL-2 signaling pathway was selected for further analysis. The results demonstrated that p-AKT was upregulated in HUVECs following treatment with lovastatin, as well as the upregulation of eNOS and downregulation of BAX. The expression levels of PTK2B, p-AKT and eNOS were downregulated in HUVECs treated with ox-LDL, and this was associated with upregulation of the mitochondrial-dependent apoptosis. Notably, this signaling cascade was inhibited or reversed by lovastatin, thus suggesting that the effects of lovastatin may be mediated via this pathway.

In the present study, *PTK2B* expression was silenced using siRNA in order to observe whether this would alter the effects of lovastatin. Notably, knockdown of *PTK2B* decreased the downstream expression of p-AKT, eNOS and BCL2, and increased the expression of BAX and cleaved caspase-3, thus confirming that PTK2B plays an important role in this cascade. In addition, knockdown of PTK2B markedly diminished the effect of ox-LDL on this cascade, including the extent to which p-AKT, eNOS and BCL2 were downregulated, and BAX and cleaved caspase-3 were upregulated. These results suggested that PTK2B may exert anti-apoptotic effects against ox-LDL-induced cytotoxicity. Consistent with this, the effects of ox-LDL on HUVEC viability and apoptosis were markedly reduced following knockdown of *PTK2B*. Therefore, the upregulation of PTK2B served an important role in the ability of lovastatin to protect against ox-LDL-induced cell injury. This result is consistent with the findings of previous studies, which demonstrated that PTK2B mediates anti-apoptotic AKT signaling ([@b40-etm-0-0-3547]), and that upregulation of PTK2B increased cell viability and mobility ([@b51-etm-0-0-3547]--[@b53-etm-0-0-3547]).

However, the present study had certain limitations. A number of genes were altered by lovastatin treatment; however, it is difficult to distinguish the 'driver' from the 'passenger' genes, since certain alterations may not be associated with the pharmacological effect of lovastatin. In addition, full integration of the gene profile according to a limited functional study of these genes was challenging, although certain bioinformatics tools were used, including KEGG and DAVID pathway analysis. Furthermore, due to the inherent limitations of microarray and bioinformatics analyses, certain observed alterations may not actually be significant. Therefore, further studies are required to fully analyze the microarray data and to present a comprehensive mechanistic view of the effects of lovastatin on endothelial cells.

In conclusion, the present study investigated the effects of lovastatin on gene expression in HUVECs, and demonstrated that the expression levels of a number of genes were regulated by lovastatin. In addition, certain genes were found to be closely associated with cell survival, in particular *PTK2B* and *BCL2*, which were upregulated. Thus, it was hypothesized that this effect of lovastatin may be beneficial against endothelial cell injury induced by ox-LDL, a known risk factor for endothelial dysfunction and atherosclerosis. Lovastatin was shown to protect against ox-LDL-induced cytotoxicity, and this protective effect was exerted via the regulation of the signaling cascade involving PTK2B, p-AKT, eNOS, BCL2, BAX and caspase-3. The present study demonstrated that high-throughput screening technology may be considered a useful tool for mechanistic analyses of drugs.

![Effect of lovastatin on the cholesterol content and gene expression profile of HUVECs. (A) Lovastatin (0.1, 0.5, 2.5 and 12.5 µM) decreased the cholesterol content of HUVECs after 24 h of treatment. (B) 0.5 µM lovastatin decreased the cholesterol content of HUVECs following 12 and 24 h of treatment. (C) Genes that were differentially expressed at 2 and 24 h of lovastatin treatment (fold-change \>1.5; false discovery rate \<0.01; green indicates downregulation and red indicates upregulation). (D) Fold-change of regulated genes after 2 and 24 h of lovastatin treatment. Data are expressed as the mean ± standard deviation of three independent experiments. \*P\<0.05 vs. the control cells. HUVECs, human umbilical vein endothelial cells.](etm-12-03-1741-g00){#f1-etm-0-0-3547}

![Critical genes regulated by lovastatin. (A) Verification of gene expression by reverse transcription-quantitative polymerase chain reaction. (B) Protein expression levels of genes regulated by lovastatin were analyzed by western blot analysis. (C) The effect of lovastatin on cell viability after 24 h of treatment, as determined by the cell counting kit-8 assay. Data are presented as the mean ± standard deviation of three independent experiments. \*P\<0.05 vs. the control cells.](etm-12-03-1741-g01){#f2-etm-0-0-3547}

![Lovastatin protects HUVECs against ox-LDL-induced cytotoxicity. Cells were treated with 20 µg/ml ox-LDL, 0.5 µM lovastatin or a combination of both for 24 h. (A) Cell viability was determined using the cell counting kit-8 assay. (B) Cell apoptosis was assessed by Annexin V and PI staining, followed by flow cytometry. (C) Percentage of apoptotic cells. (D) Protein expression was analyzed by western blotting and band intensities were determined using ImageJ software, following normalization to a control (β-actin). Data are presented as the mean ± standard deviation of three independent experiments. \*P\<0.05 vs. the control cells; ^\#^P\<0.05 vs. the ox-LDL group. HUVECs, human umbilical vein endothelial cells; ox-LDL, oxidized low-density lipoprotein; PI, propidium iodide.](etm-12-03-1741-g02){#f3-etm-0-0-3547}

![Knock-down of *PTK2B* expression attenuated ox-LDL-induced HUVEC injury. HUVECs were transiently transfected with *PTK2B* siRNA or scramble siRNA for 48 h, followed by treatment with 20 µg/ml ox-LDL for 24 h. (A) Cell viability was determined using a cell counting kit-8 assay. (B) Cell apoptosis was determined by Annexin V and PI staining, followed by flow cytometry. (C) Percentage of apoptotic cells. (D) Protein expression was analyzed by western blotting and band intensities were determined using ImageJ software following normalization to a control (β-actin). Data are presented as the mean ± standard deviation of three independent experiments. \*P\<0.05 vs. the control cells. ox-LDL, oxidized low-density lipoprotein; HUVECs, human umbilical vein endothelial cells; siRNA, small interfering RNA; PI, propidium iodide.](etm-12-03-1741-g03){#f4-etm-0-0-3547}

###### 

Gene names and polymerase chain reaction primer sequences.

  Gene name   Forward primer (5′-3′)   Reverse primer (5′-3′)
  ----------- ------------------------ ------------------------
  *BCL2*      AAAATTTCCTGCATCTCATG     TATTGGATGTGCTTTGCATT
  *PTK2B*     GCCCAGCCGACCTAAGTACAG    CGTAGGAGAGCTGGCACACA
  *MAP3K3*    GAGAGCGTGACCCGAAAGTA     GGATGTTGGCTCCCTTAATG
  *MAP4K2*    CAACTCCCAAGGTGCATATG     CGAGTAACAGGGTGAATCCA
  *CDC7*      AAGACGGAAAGGAGGGATCT     GCAGGGCTCTCATGTGAAAT
  *SNPH*      GCCAGCAACACCTATGAGAA     GGTACTGCACGAAGTCTGTCT
  *RAB25*     GCTGCAGAAGTCCCCTTACC     GGCGACAAATCTGTGTGTTG
  *OVGP1*     TTGATGGTCTTGACCTTTTC     GCAAACAGGAGCTCTTCAAT
  *ATP2B1*    CATGTGTTAGGGCCCAGATT     TCTTTGCTTGGTCAGCACTCT
  *SGK3*      TGAAATGCTGTATGGATTGC     ACTCACTCCTGGCCTCAAAC
